Cargando…
M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer
Pancreatic cancer is a malignant disease with high mortality and poor prognosis due to lack of early diagnosis and low treatment efficiency after diagnosis. Although Gemcitabine (GEM) is used as the first-line chemotherapeutic drug, chemoresistance is still the major problem that limits its therapeu...
Autores principales: | Zhao, Yongmei, Zheng, Yuanlin, Zhu, Yan, Zhang, Yi, Zhu, Hongyan, Liu, Tianqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472397/ https://www.ncbi.nlm.nih.gov/pubmed/34575569 http://dx.doi.org/10.3390/pharmaceutics13091493 |
Ejemplares similares
-
Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer
por: Zhao, Yongmei, et al.
Publicado: (2022) -
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022) -
Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017) -
Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell lines
por: Zhou, Jiarong, et al.
Publicado: (2019) -
Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
por: Shinoda, Shuhei, et al.
Publicado: (2018)